Abstract 222P
Background
Pancreatic neuroendocrine tumors (PNETs) are a subset of pancreatic malignancies, despite their relative rarity, PNETs pose significant clinical dilemmas due to their potential for aggressive behavior and limited therapeutic options. Given the scarcity of comprehensive studies in the realm of PNET therapy, this study aims to address a critical gap in our understanding of optimal treatment strategies, by investigating the survival outcomes among PNET patients who underwent different treatment modalities.
Methods
Data was collected from the SEER database for patients diagnosed with PNETs. Patients with these therapeutic approaches were included: chemotherapy, adjuvant chemotherapy and surgery; local excision of tumor NOS, partial pancreatectomy NOS, local or partial pancreatectomy and duodenectomy without distal/partial gastrectomy and with gastrectomy (Whipple), total pancreatectomy, total pancreatectomy and subtotal gastrectomy or duodenectomy, extended pancreatoduodenectomy, pancreatectomy NOS, and surgery, NOS. Based on employing the Kaplan-Meier method, survival curves were generated to compare the survival outcomes across the treatment cohorts. Data analysis was performed using IBM SPSS Statistics version 27.
Results
A cohort of 3,306 PNET patients were analyzed. Among them, 1,704 underwent surgery, 1,345 received chemotherapy only, and 257 underwent adjuvant chemotherapy. Notably, patients who underwent surgery demonstrated a markedly higher survival rate compared to those who received chemotherapy alone and those who underwent adjuvant chemotherapy (p value <0.001), with 71.8%, 15.2%, and 34.6%, respectively.
Conclusions
Patients who underwent surgery alone showed a significant 93% increase in survival compared to those who underwent adjuvant chemotherapy. Our Findings provide valuable insights into the current landscape of treatment options and to clinicians for optimal therapeutic strategies for managing PNET patients. Also highlights the pressing need for further research and clinical trials to explore the efficacy of alternative or adjunctive therapies in enhancing the prognosis of PNET patients.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.